期刊文献+

中药舒肝凉血方改善乳腺癌患者潮热的临床研究 被引量:33

Effect of Shugan Liangxue Compound for Relieving Hot Flashes in Breast Cancer Patients
在线阅读 下载PDF
导出
摘要 目的观察中药舒肝凉血方对服用三苯氧胺的乳腺癌患者潮热的改善情况。方法选择2004年10月—2006年11月乳腺癌诊断明确,服用三苯氧胺(他莫西芬tamoxifen,TAM)出现潮热症状的患者73例,随机分为治疗组(37例)和对照组(36例),治疗组予中药舒肝凉血方,对照组予安慰剂。观察潮热及睡眠改善情况。以治疗前1周每日平均潮热次数及睡眠情况作为基线。采用国际认可的Kupperman评分方法,比较治疗前后潮热及睡眠改善情况。结果可评价病例66例,治疗组33例,对照组33例。潮热症状减轻情况:治疗组潮热症状消失5例(15.2%),减轻14例(42.4%),无变化14例(42.4%);对照组无患者症状消失,减轻10例(30.3%),无变化23例(69.7%)。两组比较,差异有统计学意义(P=0.012)。睡眠改善情况:治疗组睡眠改善21例(63.6%),无变化12例(36.4%);对照组睡眠改善13例(39.4%),无变化20例(60.6%)。两组比较,差异有统计学意义(P=0.002)。结论中药舒肝凉血方可减轻服用三苯氧胺乳腺癌患者的潮热症状并改善睡眠情况。 Objective To observe the effect of Shugan Liangxue Compound (SLC) for relieving hot flashes in breast cancer patients medicated with tamoxifen. Methods A randomized, double blind clinical trial for observing the therapeutic effects of SLC was carried out on 73 breast cancer patients hospitalized from October 2004 to November 2006, who were treated with tamoxifen, and revealed hot flashes. They were radomly as- signed to two groups, the 37 in the treated group treated by SLC, and the 36 in the control group treated with pla- cebo. Taking the improvement of hot flashes as an end point index and that of sleep as a secondary index, the effects of treatment were compared by Kupperman scoring with the average times of hot flashes per day and condition of sleep within 1 week before treatment as baseline. Results The effects on 66 patients (33 in the treated group and 33 in the control group) were evaluable. In the treated group hot flashes disappeared in 5 patients (15.2%), relieved in 14 (42.4%) and unchanged in 14 (42.4%) ; while in the control group, it disappeared in none, relieved in 10 (30.3%) and unchanged in 23 (69.7%), comparison between groups showed significant difference (P=0.012). As for the condition of sleep, it was improved in 21 (63.6%) and unchanged in 12 (36.4%) in the treated group; while the condition of sleep in the control group was improved in 13 (39.4%) and unchanged in 20 (60.6%), also with significant difference between the two groups (P = 0. 002 ). Conclusion SLC is effective in alleviating tamoxifen-induced hot flashes and improving the condition of sleep.
出处 《中国中西医结合杂志》 CAS CSCD 北大核心 2009年第1期30-33,共4页 Chinese Journal of Integrated Traditional and Western Medicine
基金 北京市首都医学发展科研基金资助项目(No.03-Ⅱ-07)
关键词 舒肝凉血方 乳腺癌 潮热 睡眠状况 Shugan Liangxue Compound breast cancer hot flashes condition of sleep
  • 相关文献

参考文献27

  • 1Carpenter JS, Andrykowski MA, Cordova M, et al. Hot flash in postmenopausal women treated for breast carcinoma:prevalence, severity, correlates, management, and relation to quality of life [J]. Cancer, 1998,82(9):1682-1691.
  • 2Kronenberg F. Hot flashes: phenomenology, quality of life, and search for treatment options[J]. Exp Gerontol,1994,29(3-4):319-336.
  • 3Couzi R J, Helzlsouer K J, Fetting JH. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy[J]. J Clin Oncol, 1995,13( 11 ): 2737-2744
  • 4赵翌,刘基巍,Xin Shelly Wang,李萍萍.肿瘤常见症状及中医症状调查量表的设计[J].中华肿瘤防治杂志,2008,15(11):861-863. 被引量:44
  • 5刘端祺,李小梅,王艳梅,王展宏(校对).奥施康定治疗中重度癌痛疗效观察[J].中国肿瘤临床,2006,33(16):934-936. 被引量:41
  • 6李萍萍,王薇,谢玉泉.舒肝凉血方对体内雌激素影响的实验研究[J].中华肿瘤杂志,2003,25(5):445-447. 被引量:9
  • 7孙红,李萍萍,解云涛.舒肝凉血方与三苯氧胺合用对人乳腺癌细胞MCF-7生长及ER表达影响[J].中国肿瘤,2005,14(9):607-610. 被引量:12
  • 8Loprinzi CL, Kugler JW, Sloan JA,et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial [J ]. Lancet, 2000,356 (9247) :2059- 2063.
  • 9Loprinzi CL, Sloan JA, Perez EA,et al. Phase Ⅲ evaluation of fluoxetine for treatment of hot flashes[ J]. J Clin Oncol,2002,20(6):1578-1583.
  • 10Stearns V, Beebe KL, lyengar M, et al. Paroxetine controlled release in the treatment of menopausal hot flash-a randomized controlled trial [ J ]. JAMA, 2003,289(21 ) :2827-2834.

二级参考文献35

  • 1By Vered Steams, Edward P Gelmann. Does tamoxifen cause cancer in Humans? Clin Oncol, 1998,16:779-792.
  • 2Rutqvst LE, Johansson H, Signomklao T, et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Nail Cancer Inst, 1995, 87:645.
  • 3孙燕 周际昌.临床肿瘤内科手册[M].北京:人民卫生出版社,2003.586-591.
  • 4Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study[J].J Natl Cancer Inst, 1998,90:1371-1388.
  • 5Veronesi U, Maisonneuve P, Rotmensz N, et al. Italian randomized trial among women with hysterectomy:tamoxifen and hormone-dependent breast cancer in high-risk women[J]. J Natl Cancer Inst, 2003,95:160-165.
  • 6Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast cancer prevention trials [J].Lancet, 2003,361:296-300.
  • 7Buzdar AU. Endocrine therapy in the treatment of metastatic breast cancer[J]. Semin Oncol, 2001,28: 291-304.
  • 8Krista A. Power and Lilian U. Thompson. ligand-induced regulation of ERα and ERβ is indicative of human breast cancer cell proliferation [J]. Breast Cancer Res Treat,2003,81:209-221.
  • 9Iain R,Hutcheson L, Janice M, et al. Oestrogen receptormediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells [J]. Breast Cancer Res Treat, 2003,81:81-93.
  • 10Wijayaratne AL, McDonnell DP. The human estrogen receptor is a ubiquitinated protein whose stability affected differentially by agonists, antagonists, and selective receptor modulators[J]. J Biol Chem, 2001,276:35684-35692.

共引文献141

同被引文献480

引证文献33

二级引证文献183

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部